De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients (clinicaltrials.gov) - Apr 2, 2026 - P3 | N=30 | Active, not recruiting | Sponsor: Virginia Commonwealth University | N=60 ➔ 30 | Trial primary completion date: Mar 2026 ➔ Sep 2026
Enrollment change • Trial primary completion date • Cytomegalovirus Infection • Transplantation • CYP3A5
|